secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001171843-25-004062
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics stockholders approve 475,000-share increase in incentive plan
--------------------------------------------------------------------------------

- Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.
- All three Class II director nominees elected: Blanchard, Capper, Larsen.
- Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.
- Deloitte & Touche ratified as independent auditor for fiscal 2025.
- Annual meeting had 86.13% of voting power present; no opposition to board's solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/0001171843-25-004062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/f8k_062425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer